Dr Garner acquired 15,000 shares and Coffey bought 10,000 shares to increase their holdings to 200,000 and 251,474 respectively.
Initial success for key R&D programs
Kazia had a transformational year in 2019 with initial clinical efficacy read-outs from both its key R&D programs.
This included initial data from the ongoing phase 2 clinical trial of GDC-0084 (paxalisib) in glioblastoma which showed concrete signals of clinical efficacy.
2019 was also a positive year for the Cantrixil program, with positive data reported from the ongoing phase I study in ovarian cancer
These clinical trial results translated into a material re-rating of the company’s valuation.
On January 1 2019 Kazia shares traded at 34 cents. On December 31 2019 they traded at 60 cents.